Literature DB >> 20089736

Role of P-glycoprotein in the disposition of macrocyclic lactones: A comparison between ivermectin, eprinomectin, and moxidectin in mice.

Solange Kiki-Mvouaka1, Cécile Ménez, Christiane Borin, Faouri Lyazrhi, Magali Foucaud-Vignault, Jacques Dupuy, Xavier Collet, Michel Alvinerie, Anne Lespine.   

Abstract

Macrocyclic lactones (MLs) are lipophilic anthelmintics and substrates for P-glycoprotein (P-gp), an ATP-binding cassette transporter involved in drug efflux out of both host and parasites. To evaluate the contribution of P-gp to the in vivo kinetic disposition of MLs, the plasma kinetics, brain concentration, and intestinal excretion of three structurally different MLs (ivermectin, eprinomectin, and moxidectin) were compared in wild-type and P-gp-deficient [mdr1ab(-/-)] mice. Each drug (0.2 mg/kg) was administered orally, intravenously, or subcutaneously to the mice. Plasma, brain, and intestinal tissue concentrations were measured by high-performance liquid chromatography. The intestinal excretion rate after intravenous administration was determined at different levels of the small intestine by using an in situ intestinal perfusion model. P-gp deficiency led to a significant increase in the area under the plasma concentration-time curve (AUC) of ivermectin (1.5-fold) and eprinomectin (3.3-fold), whereas the moxidectin AUC was unchanged. Ivermectin and to a greater extent eprinomectin were both excreted by the intestine via a P-gp-dependent pathway, whereas moxidectin excretion was weaker and mostly P-gp-independent. The three drugs accumulated in the brains of the mdr1ab(-/-) mice, but eprinomectin concentrations were significantly lower. We concluded that eprinomectin disposition in mice is controlled mainly by P-gp efflux, more so than that of ivermectin, whereas moxidectin disposition appears to be mostly P-gp-independent. Given that eprinomectin and ivermectin have higher affinity for P-gp than moxidectin, these findings demonstrated that the relative affinity of MLs for P-gp could be predictive of the in vivo kinetic behavior of these drugs.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20089736     DOI: 10.1124/dmd.109.030700

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  23 in total

1.  Preclinical development of moxidectin as a novel therapeutic for alcohol use disorder.

Authors:  Nhat Huynh; Natalie Arabian; Anna Naito; Stan Louie; Michael W Jakowec; Liana Asatryan; Daryl L Davies
Journal:  Neuropharmacology       Date:  2016-09-15       Impact factor: 5.250

2.  The antihelminthic moxidectin enhances tonic GABA currents in rodent hippocampal pyramidal neurons.

Authors:  Jay Spampanato; Anne Gibson; F Edward Dudek
Journal:  J Neurophysiol       Date:  2018-01-24       Impact factor: 2.714

3.  Toxocara encephalitis presenting with autonomous nervous system involvement.

Authors:  F Caldera; M E Burlone; C Genchi; M Pirisi; E Bartoli
Journal:  Infection       Date:  2012-09-21       Impact factor: 3.553

Review 4.  Clinical aspects of eosinophilic meningitis and meningoencephalitis caused by Angiostrongylus cantonensis, the rat lungworm.

Authors:  Gerald S Murphy; Stuart Johnson
Journal:  Hawaii J Med Public Health       Date:  2013-06

5.  Δ²,³-ivermectin ethyl secoester, a conjugated ivermectin derivative with leishmanicidal activity but without inhibitory effect on mammalian P-type ATPases.

Authors:  François Noël; Paulo Henrique Cotrim Pimenta; Anderson Rouge Dos Santos; Erick Carlos Loureiro Tomaz; Luis Eduardo Menezes Quintas; Carlos Roland Kaiser; Claudia Lucia Martins Silva; Jean-Pierre Férézou
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2010-11-19       Impact factor: 3.000

6.  Inhibition of the Human ABC Efflux Transporters P-gp and BCRP by the BDE-47 Hydroxylated Metabolite 6-OH-BDE-47: Considerations for Human Exposure.

Authors:  Satori A Marchitti; Christopher S Mazur; Caleb M Dillingham; Swati Rawat; Anshika Sharma; Jason Zastre; John F Kenneke
Journal:  Toxicol Sci       Date:  2016-10-23       Impact factor: 4.849

Review 7.  Moxidectin and the avermectins: Consanguinity but not identity.

Authors:  Roger Prichard; Cécile Ménez; Anne Lespine
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2012-04-14       Impact factor: 4.077

Review 8.  P-glycoproteins and other multidrug resistance transporters in the pharmacology of anthelmintics: Prospects for reversing transport-dependent anthelmintic resistance.

Authors:  Anne Lespine; Cécile Ménez; Catherine Bourguinat; Roger K Prichard
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2011-11-07       Impact factor: 4.077

9.  Relative neurotoxicity of ivermectin and moxidectin in Mdr1ab (-/-) mice and effects on mammalian GABA(A) channel activity.

Authors:  Cécile Ménez; Jean-François Sutra; Roger Prichard; Anne Lespine
Journal:  PLoS Negl Trop Dis       Date:  2012-11-01

10.  Differences in P-glycoprotein activity in human and rodent blood-brain barrier assessed by mechanistic modelling.

Authors:  Laurens F M Verscheijden; Jan B Koenderink; Saskia N de Wildt; Frans G M Russel
Journal:  Arch Toxicol       Date:  2021-07-15       Impact factor: 5.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.